Cargando…

Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques

Medroxyprogesterone acetate (MPA) injectable products are a key commodity for reproductive health and are available in the global market from a variety of manufacturing sources. Depending on the climatic zone conditions of the destination country for product use, MPA injectables are at risk of expos...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, David, Harmon, Christopher L., Jia, Xiao, Kesselring, Allen, Hatcher, Danielle, Grayson, Katie, Ayres, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322552/
https://www.ncbi.nlm.nih.gov/pubmed/32480200
http://dx.doi.org/10.1016/j.jpba.2020.113352
_version_ 1783551665352212480
author Jenkins, David
Harmon, Christopher L.
Jia, Xiao
Kesselring, Allen
Hatcher, Danielle
Grayson, Katie
Ayres, Jennifer
author_facet Jenkins, David
Harmon, Christopher L.
Jia, Xiao
Kesselring, Allen
Hatcher, Danielle
Grayson, Katie
Ayres, Jennifer
author_sort Jenkins, David
collection PubMed
description Medroxyprogesterone acetate (MPA) injectable products are a key commodity for reproductive health and are available in the global market from a variety of manufacturing sources. Depending on the climatic zone conditions of the destination country for product use, MPA injectables are at risk of exposure to adverse transport and storage conditions. Analytical methods are available that quantify impurity levels in MPA and MPA injectable products, but minimal information is publicly available on the source of impurity and degradation product generation or the safety risk of these compounds. Forced degradation studies were conducted on MPA and MPA injectables to gain a better understanding of potential sources of impurities and degradation products. Furthermore, QSAR analysis was conducted to assess the toxicity risk of known impurities. More impurities were generated under acidic, basic, light, and oxidative forced degradation conditions relative to thermal degradation, however thermal exposure is the most likely adverse condition to be experienced by these products. Even if impurities are present in MPA injectables, QSAR analysis found that known impurities for MPA are apparently no more of a safety risk than MPA.
format Online
Article
Text
id pubmed-7322552
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-73225522020-08-05 Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques Jenkins, David Harmon, Christopher L. Jia, Xiao Kesselring, Allen Hatcher, Danielle Grayson, Katie Ayres, Jennifer J Pharm Biomed Anal Article Medroxyprogesterone acetate (MPA) injectable products are a key commodity for reproductive health and are available in the global market from a variety of manufacturing sources. Depending on the climatic zone conditions of the destination country for product use, MPA injectables are at risk of exposure to adverse transport and storage conditions. Analytical methods are available that quantify impurity levels in MPA and MPA injectable products, but minimal information is publicly available on the source of impurity and degradation product generation or the safety risk of these compounds. Forced degradation studies were conducted on MPA and MPA injectables to gain a better understanding of potential sources of impurities and degradation products. Furthermore, QSAR analysis was conducted to assess the toxicity risk of known impurities. More impurities were generated under acidic, basic, light, and oxidative forced degradation conditions relative to thermal degradation, however thermal exposure is the most likely adverse condition to be experienced by these products. Even if impurities are present in MPA injectables, QSAR analysis found that known impurities for MPA are apparently no more of a safety risk than MPA. Elsevier Science 2020-08-05 /pmc/articles/PMC7322552/ /pubmed/32480200 http://dx.doi.org/10.1016/j.jpba.2020.113352 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jenkins, David
Harmon, Christopher L.
Jia, Xiao
Kesselring, Allen
Hatcher, Danielle
Grayson, Katie
Ayres, Jennifer
Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title_full Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title_fullStr Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title_full_unstemmed Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title_short Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques
title_sort forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of hplc, mass spectrometry, and qsar techniques
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322552/
https://www.ncbi.nlm.nih.gov/pubmed/32480200
http://dx.doi.org/10.1016/j.jpba.2020.113352
work_keys_str_mv AT jenkinsdavid forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT harmonchristopherl forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT jiaxiao forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT kesselringallen forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT hatcherdanielle forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT graysonkatie forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques
AT ayresjennifer forceddegradationstudiesofmedroxyprogesteroneacetateinjectablesuspensions150mgmlwithimplementationofhplcmassspectrometryandqsartechniques